TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of extensive stage small-cell lung cancer (ES-SCLC),\* including malignant pleural effusion~2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~3. No prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC~4. Measurable disease as defined by the RECIST criteria~5. Adequate organ function as defined by the protocol~6. Female patients of child bearing potential (CBP) must agree to use of reliable method of birth control during and for 3 months following treatment~7. Patients must sign informed consent document~8. Patients must be ≥ 18 years of age~9. Patients with brain metastases that have been adequately treated and are determined to be controlled by the attending physician are eligible~10. Patients who have had prior malignancies are eligible if they are ≥ 5 years from diagnosis free of disease or the attending physician believes the patient's prognosis is best defined by the ES-SCLC (if questions concerning this eligibility criteria arise, please contact the principal investigator)~(\*)ES-SCLC defined as metastases outside the chest, pulmonary metastases, or contralateral metastases (supraclavicular or hilar) nodes that could not be included with a reasonable single radiation port. Patients with malignant pleural effusions are considered extensive stage.~Exclusion Criteria:~1. Received treatment within the last 30 days with a drug that has not received Food and Drug Administration (FDA) approval for any indication at the time of study entry~2. Pregnancy or breast feeding~3. Serious active infection that would require a prolonged course (4-6 weeks) of antibiotics or would compromise the safety of the patient or compromise the patient's ability to complete the study~4. Symptomatic brain metastases~5. Grade ≥ 2 neuropathy using NCI CTCAE version 3.0 criteria~6. Previous anaphylactic reaction to carboplatin, paclitaxel, and docetaxel~7. Severe or uncontrolled cardiac disease, defined as uncontrolled or unstable angina, myocardial infarction in the last month, uncontrolled congestive heart failure (≥ 3 admissions for congestive heart failure in the 3 months prior to diagnosis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
- Arm B (Type: EXPERIMENTAL): Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed low-grade glioma including astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2.~* Tumor is supratentorially located and measureable.~* Disease that has not received prior radiation, radiosurgery, chemotherapy, or other investigational treatment directed at the brain tumor at any time. Previous surgical procedures is allowed.~* Age ≥ 18 years.~* Life expectancy \> 12 weeks.~* Either not receiving steroids for disease symptoms or are on stable dose of steroids for at least 5 days.~* Karnofsky Performance Status (KPS) ≥ 60%~* Adequate hematologic function evidenced by:~  * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L~ * Platelet count ≥ 100 x 109/L~ * Hemoglobin ≥ 9.0 g/dL~* Adequate renal function evidenced by:~  * AST/SGOT and ALT/SPGT ≤ 2.5 X institutional upper limit of normal~ * Total bilirubin ≤ 1.5 x institution's ULN~ * Serum creatinine ≤ 1.5 x institution's ULN~Exclusion Criteria:~* Pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors are not eligible.~* Current or anticipated use of other investigational agents.~* Implanted electronic medical device in the brain (e.g., deep brain stimulator, vagus nerve stimulator, programmable shunt).~* Patients who are less than 4 weeks from surgery or have insufficient recovery from surgical-related trauma or wound healing.~* Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements).~* Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.~* Pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): NovoTTF-200A
- Arm B (Type: ACTIVE_COMPARATOR): NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Quadriceps Muscle Electrostimulation Used in Patients Suffering From Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years~* Patient suffering from cystic fibrosis~* Patient has at least three measures of maximum expiratory volume per second \<= 45% of the theory among the 6 last measures performed~* Affiliation to French social security~* Capacity to consent~Exclusion Criteria:~* Pregnant women~* Contraindication to application of magnetic field~* Pacemaker~* History of neurosurgical intervention~* Presence of metallic particles near the stimulation site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
- 2 (Type: ACTIVE_COMPARATOR): Usual sport activity, performed prior to an endurance retraining program using a cycloergometer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Admitted to pediatric intensive care unit and have the diagnosis of acute respiratory failure~* 44 weeks post conceptional age to 16 years of age~* Oxygenation Index (OI) \>=12 cm H2O/mmHg (as determined by two separate measurement taken 30 minutes to 4 hours apart)~* Recent chest x-ray (within 24 hours) showing at least unilateral infiltrations~* Mechanically ventilated \<= 7 days~Exclusion criteria:~* Immunocompromised~* Received a bone marrow transplant~* Active oncological condition~* Persistent right to left intracardiac shunt~* Cardiovascular surgery within the last 14 days~* Status asthmaticus~* Decision by primary care physician not to provide full support~* Received treatment with nitric oxide for inhalation or other investigational medications within 24 hours prior to study initiation, participating in surfactant trials~* Chronically ventilated~* Pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): Nitrogen gas
- 1 (Type: EXPERIMENTAL): Inhaled Nitric Oxide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 3 to 12 years (inclusive)~2. IXT for distance or constant IXT for distance and either IXT or exophoria for near~3. IXT size of \> 10PD~4. Visual acuity in worse eye of at least 0.3 logMar (Snellen 6/12)~5. Visual acuity of no greater than 2 lines between eyes~6. Parents or guardian willing to accept randomization, and to continue with observation or treatment for at least 6-12 months, unless deterioration of strabismus or fall in best corrected visual acuity of worse than 0.3logMar (Snellen 6/12) in either eye~7. Investigator willing to observe IXT untreated for at least 1 year~Exclusion Criteria:~1. Previous non-surgical treatment for IXT, or patch treatment for amblyopia within the last year~2. Prior strabismus, intraocular or refractive surgery or botulinium injection~3. Surgery planned within the next year~4. Prematurity (birth weight \< 1500g, gestational age \< 34 weeks), systemic illness (eg. cerebral palsy), syndrome (including craniosynostosis) or learning disability~5. Any ocular abnormality (cornea, lens or central retina); nystagmus or conditions that limit eye movements.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Non-surgical therapy (Type: EXPERIMENTAL): patching or fusion exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating Transcranial Alternating Current Stimulation (tACS) Preconditioning Effects on Resting and Active Motor Threshold

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Montreal Cognitive Assessment score greater than or equal to 26~Exclusion Criteria:~* being pregnant~* having any metallic implants in the head or upper body~* having a pacemaker~* having a history of seizures~* having a diagnosed major psychotic disorder~* having any nervous system medication (depression, anxiety, sleep, pain, etc.) on a daily basis~* having a brain injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Participants (Type: EXPERIMENTAL): Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* Ages 3-17~* Closed distal forearm fracture requiring reduction under sedation in the Emergency Department~* Fracture involves the distal third of the forearm~Exclusion Criteria:~* Multiple trauma victims~* Associated nerve or vascular damage~* Associated elbow or humerus injury~* Sensitivity or allergy to lidocaine~* Contraindications to procedural sedation~* Previous attempts at reduction for the same injury

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
- Normal Saline (Type: PLACEBO_COMPARATOR): Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Analgesia Versus No Analgesia: Study for External Cephalic Version

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* 37 + weeks gestation~* No previous attempt at ECV in this pregnancy~* No fetal abnormality~Exclusion Criteria:~* No previous uterine surgery~* Any contraindication for vaginal delivery~* Contra-indications to regional analgesia: uncorrected hypovolemia, coagulopathy (including anti-coagulants but not low-dose \[100mg\] aspirin), infection or inflammation of the skin overlying the lumbar area, raised intra-cranial pressure, hypersensitivity to amide local anesthetic agents.~* Patient refusal for regional analgesia~* Previous history of meningitis, neuropathy, or severe back pain with neurological radiation~* Poor communication (no Hebrew or English spoken, deafness, blindness, serious intellectual impairment or psychiatric disorder)~* Morbid obesity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- External cephalic version with spinal anesthesia (Type: EXPERIMENTAL): External cephalic version with spinal anesthesia
- External cephalic version without spinal anesthesia (Type: ACTIVE_COMPARATOR): External cephalic version without spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Type I Supracondylar Fractures of the Humerus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged 4-12 years who present to the Emergency department at BC Children's hospital with a history of elbow trauma, and are diagnosed by the staff emergency physician to have a Type I supracondylar fracture of the humerus (as seen on AP and lateral radiographs of the elbow)~Exclusion Criteria:~* patients with neurovascular compromise associated with the fracture~* a pre-existing diagnosis of metabolic or structural bone disease that predisposes them to fractures~* presence of other fractures of the ipsilateral upper extremity

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Cast (Type: ACTIVE_COMPARATOR): Above elbow fiberglass cast with a collar-and-cuff
- Splint (Type: ACTIVE_COMPARATOR): Long arm posterior plaster splint with a collar-and-cuff
- Tape (Type: ACTIVE_COMPARATOR): Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female patients, 18 years or older~* Moderate to severe plaque-type psoriasis, candidate for systemic therapy~* Diagnosis of NAFLD by either ultrasound at Screening or liver histology within 6 months before Baseline~* BMI \> 25 kg/ m 2~* ALT 1.2 to 3.0 × ULN~* MRI confirmed Liver fat ≥ 8% at Screening~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque-type Psoriasis~* Drug induced psoriasis~* Pregnant or nursing (lactating) women~* Women of child bearing potential unless they are using effective methods of contraception~* Ongoing use of prohibited treatments~* Previous treatment with biological drug targeting IL-17 or the IL-17 receptor~* Past medical history record of infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to Screening~* Unstable weight over the last 6 months prior to Screening.~* Type I diabetes, or uncontrolled diabetes (Type I or Type II) defined as HbAlc ≥ 10% at screening.~* Evidence of hepatic decompensation or severe liver impairment or cirrhosis~* History of liver transplantation or planned liver transplant or biliary diversion.~* Presence or history of other liver disease~* Current, or history of, significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening~* Prior or planned bariatric surgery~* Inability or unwillingness to undergo MRI of the abdomen~* Past medical history record of infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational Arm - secukinumab (Type: EXPERIMENTAL): secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
- Control Arm - placebo (Type: PLACEBO_COMPARATOR): placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed and dated by study patient and investigator/authorized physician~* Minimum age of 18 years~* Ability to understand the nature and requirements of the study~* ESKD patients on maintenance hemodialysis with a minimum of 4hrs three times a week at the time of recruitment and a dialysis vintage ≥3 months in NC clinics~* Patients that already received three doses against COVID-19 as detailed in the manufacturer's instructions~* Patients that are scheduled to receive a fourth vaccine dose of either Comirnaty (BioNTech/Pfizer) or Spikevax (Moderna) after approval of respective national authority.~Exclusion Criteria:~* Any conditions which could interfere with the patient's ability to comply with the study~* Participation in an interventional clinical study during the preceding 30 days~* Previous participation in the same study~* Patients with proven current COVID-19 infection as identified by routine clinical practice~* Patient in therapy with immunosuppressive medications / immunomodulators~* Patients who already received a fourth COVID-19 vaccination dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* body weight 40-100kg~* diagnosed as systemic lupus erythematosus, (according to American College of Rheumatology Diagnostic Criteria,1997)~* diagnosed as type III/ IV of lupus nephritis by renal biopsy within 6 months~* 24hr proteinuria ≥2g and/or active urinary sediments~Exclusion Criteria:~* receiving immunosuppressant~* receiving routine treatment of tacrolimus and leflunomide within 1 month~* receiving nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 months before the study~* history of allergy to tacrolimus and leflunomide~* anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed over 2 weeks before recruitment~* planning to receive kidney transplantation or in the near future or having a history of undergoing kidney transplantation~* serum creatinine (Scr) ≥3mg/dl or estimated glomerular filtration rate (eGFR) \< 30ml/min~* diabetes mellitus patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- tacrolimus group (Type: EXPERIMENTAL): tacrolimus capsule + leflunomide placebo
- leflunomide group (Type: ACTIVE_COMPARATOR): tacrolimus placebo + leflunomide tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues